GHK-Cu peptide for hair and skin: what the evidence shows

What did @evolvedmedicalhealth actually say?

The video is a quick hallway-style interview where a practice manager describes "GLOW" as their most popular peptide product. He says it "consists of three peptides" -- BPC-157, TB-500, and GHK-Cu -- and that they "work internally" as part of "regenerative therapy." That is the entire clinical argument. No dosing, no mechanism, no patient outcomes. The claim is essentially: these three peptides are bundled together and people seem to like them. Credit where it is due: the speaker does not claim this blend cures anything. But he also provides almost no substantive information about what these peptides actually do or what the evidence looks like. For a clinic promoting a compounded product to a public audience, that vagueness is a problem worth examining.

Does the science back this up?

Each peptide in this blend has some research behind it, but the quality varies considerably, and the combination itself has not been studied as a unit. BPC-157 is the most researched of the three. Animal studies have shown it accelerates wound healing and has anti-inflammatory effects, with researchers like Sikiric et al. (2018, Current Pharmaceutical Design) documenting tissue repair activity in rodent models. The problem: no completed randomized controlled trials in humans exist yet. TB-500, a synthetic fragment of thymosin beta-4, has shown similar wound-healing and angiogenic properties in preclinical work (Goldstein et al., 2012, Annals of the New York Academy of Sciences), but again, human trial data is thin. GHK-Cu is the most skin-specific of the three. Pickart and Margolina (2018, Cosmetics) documented its role in collagen synthesis and skin remodeling, and there is reasonable cosmetic dermatology literature supporting topical GHK-Cu. Whether systemic injection improves skin and hair outcomes beyond what topical application achieves is not established. The combination of all three as a single injectable product has no published clinical trial data at all.

What did they get wrong (or right)?

The speaker did not make outright false claims, which is something. He did not say this blend reverses aging or regrows hair in bald patients. That restraint matters. What he got wrong -- or at least incomplete -- is framing this as a straightforward, popular clinical offering without acknowledging that all three peptides are investigational compounds. BPC-157 is not FDA-approved. TB-500 is not FDA-approved. GHK-Cu in injectable form is not FDA-approved. These are compounded peptides, meaning they are prepared by compounding pharmacies outside the standard drug approval process. The FDA has raised concerns about certain peptides being used in compounded preparations. Calling this "regenerative therapy" without that context is misleading by omission. The phrase "work internally, understood in your health" is also meaninglessly vague. It sounds reassuring but communicates nothing about mechanism, safety, or expected outcomes.

What should you actually know?

If you are considering a peptide blend like this, here is what the evidence actually supports right now. GHK-Cu has the strongest dermatological evidence of the three, particularly for skin texture and collagen support, though most of that data is on topical formulations. BPC-157 and TB-500 have compelling preclinical data for tissue repair, but neither has cleared human clinical trials. Combining them into one product does not multiply their proven benefits; it multiplies the unknowns. Injectable compounded peptides carry real risks, including infection at injection sites, batch-to-batch variability in compounded products, and unknown long-term systemic effects. Anyone considering this should be working with a licensed clinician who reviews their full health history, not making decisions based on a 30-second TikTok interview with a practice manager. The absence of bold false claims here should not be mistaken for a clean bill of evidence.